Defining and treating high-risk multiple myeloma
Usmani SZ (1), Rodriguez-Otero P (2), Bhutani M (1), Mateos MV (3), Miguel JS (2).
(1) Department of Hematologic Oncology, Blood Disorders and Bone Marrow Transplantation, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
(2) Department of Hematology, Clínica Universidad de Navarra, CIMA, IDISNA, Navarra, Spain.
(3) Department of Hematology, University hospital of Salamanca, IBSAL, Salamanca, Spain.
Multiple myeloma (MM) is more recently being recognized as a heterogeneous group of disease with variability in outcomes based on specific clinical and biologic predictors. MM patients can be broadly categorized into standard, intermediate and high risk for disease relapse, morbidity and mortality.
The high-risk features include patient-specific factors such as old age, poor performance status and comorbidities; clinical features such as primary plasma cell leukemia and extramedullary disease; disease-specific biologic features such as deletion 17p, t(4;14) and high-risk gene expression profiling signatures.
The current paper reviews the available data on best therapeutic approaches for high-risk MM.
CITATION Leukemia. 2015 Nov;29(11):2119-25. doi: 10.1038/leu.2015.209. Epub 2015 Aug 12.